Amyotrophic Lateral Sclerosis Treatment Market, By Type (Sporadic ALS and Familial ALS), By Treatment Type, By Distribution Channel, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Amyotrophic Lateral Sclerosis Treatment Market size was valued at US$ 674.90 Million in 2024, expanding at a CAGR of 6.30% from 2025 to 2032.
The increasing incidence and prevalence of amyotrophic lateral sclerosis (ALS), particularly in its sporadic form, is a key factor shaping the growth of the ALS treatment market. Sporadic ALS accounts for approximately 90–95% of all ALS cases and is becoming more common due to factors such as aging demographics, environmental exposures, and underlying genetic predispositions. This upward trend in sporadic ALS cases is driving a rising demand for more effective treatment options. According to the Centers for Disease Control and Prevention (CDC), more than 16,000 individuals in the United States are currently living with ALS, with approximately 5,000 new cases diagnosed annually. On a global scale, ALS affects between 2 to 5 people per 100,000. In response, pharmaceutical companies, academic institutions, and government bodies are increasing their investments in research and development, fueling innovation and expanding the treatment pipeline. Despite these advancements, the high cost of therapies remains a significant barrier, potentially limiting patient access and hindering overall market growth.
Amyotrophic Lateral Sclerosis Treatment Market- Market Dynamics
Advancements in Multidisciplinary Care and Innovative Therapies for Improved Patient Outcomes
Amyotrophic Lateral Sclerosis (ALS) is a debilitating neurodegenerative disease that progressively impairs nerve cells in the brain and spinal cord, resulting in muscle weakness, loss of mobility, and eventually respiratory failure. The ALS treatment market is primarily centered on therapies that aim to slow disease progression, alleviate symptoms, and enhance the overall quality of life for patients. As ALS affects not only physical abilities but also cognitive and social functions, its impact is multifaceted and complex. Managing the disease effectively requires a comprehensive, patient-centric approach that addresses both physical and psychological needs. To achieve this, a coordinated, multidisciplinary care model is often necessary—bringing together neurologists, physical therapists, occupational therapists, speech-language pathologists, and mental health professionals. This collaborative strategy is essential for optimizing symptom control, extending survival, and maintaining the patient’s functional independence and emotional well-being. As research advances, newer therapeutic interventions are being developed to support this integrated care approach, offering hope for improved patient outcomes.
Amyotrophic Lateral Sclerosis Treatment Market- Segmentation Analysis:
The Global Amyotrophic Lateral Sclerosis Treatment Market is segmented based on Type, Treatment Type, Distribution Channel, and Region.
The market for Amyotrophic Lateral Sclerosis (ALS) is categorized into two segments based on type: Sporadic ALS and Familial ALS. Sporadic ALS (sALS) accounts for approximately 90–95% of all ALS cases, making it the dominant form of the disease. As sALS lacks a clear genetic cause, treatment strategies focus on disease modification, symptom management, and supportive care. FDA-approved drugs like Riluzole and Edaravone are used in both sALS and familial ALS, reinforcing sALS as the primary market driver. Additionally, most investigational therapies, including Masitinib and CNM-Au8, are being developed specifically for sALS, aiming to improve treatment efficacy and increase market reach through targeted innovation.
The market is categorized into two segments based on Treatment Type: Medication, Stem Cell Therapy, and Other Treatment Types. Medication represents the dominant segment in the Amyotrophic Lateral Sclerosis (ALS) treatment market, as it plays a critical role in slowing disease progression and managing symptoms. The increasing use of FDA-approved drugs like Riluzole, Edaravone, and Tofersen, along with robust clinical pipelines for emerging therapies, is driving market growth. Medications constitute the largest share of ALS treatment expenditures, with hospital pharmacies being key in administering intravenous options like Edaravone. The rising global prevalence of ALS, combined with growing healthcare investments, is further accelerating the adoption of these pharmaceutical treatments.
The market is categorized into four segments based on Distribution channels: Hospital Pharmacies, Online Providers, and Drug Stores, as well as Retail Pharmacies. Hospital pharmacies are integral to the ALS treatment landscape, overseeing the dispensing and management of specialized medications, including advanced therapies requiring expert handling. They play a key role in administering symptom-relief drugs such as Baclofen and Tizanidine, as well as treatments supporting respiratory function. With many ALS clinical trials conducted in hospital settings, these pharmacies often gain early access to investigational therapies. Furthermore, hospital pharmacists provide essential services like medication counseling and nutritional support, particularly for patients with dysphagia, ensuring comprehensive care and enhancing treatment adherence and patient outcomes.
Amyotrophic Lateral Sclerosis Treatment Market- Geographical Insights
North America dominates the Amyotrophic Lateral Sclerosis (ALS) treatment market, largely fueled by the rising demand for gene therapies and significant advancements in biotechnology. The United States leads this growth, supported by a robust network of biotech companies and research institutions dedicated to ALS innovation. According to Springer Nature, the number of patients in the U.S. receiving gene or stem cell therapy was approximately 12,000 in 2020, with projections suggesting a surge to over 340,000 by 2030. This trend highlights the region’s pivotal role in accelerating the adoption of advanced therapeutic solutions. Europe holds the position as the second-largest market, with strong emphasis on clinical research and public health initiatives aimed at improving awareness and early diagnosis of ALS. Meanwhile, the Asia Pacific region is witnessing the fastest growth in the ALS treatment market, driven by a rising incidence of ALS, increasing healthcare expenditures, and ongoing improvements in healthcare infrastructure, which collectively support greater access to diagnosis and treatment across emerging economies.
Amyotrophic Lateral Sclerosis Treatment Market- Competitive Landscape:
The competitive landscape of the Amyotrophic Lateral Sclerosis (ALS) treatment market is marked by significant rivalry among pharmaceutical and biotechnology companies focused on developing effective solutions for this challenging neurodegenerative disease. The market comprises a mix of approved therapies and a robust pipeline of investigational drugs, many of which are in various stages of clinical development. Companies are increasingly investing in innovative treatment modalities, including gene therapies, stem cell approaches, and neuroprotective agents, to address the persistent unmet needs in ALS care. This drive for innovation is supported by strategic collaborations, acquisitions, and increased funding from both public and private sectors. The rapid pace of research and technological advancement is continuously reshaping market dynamics, encouraging the introduction of novel and more accessible treatment options. As a result, the ALS treatment sector remains highly dynamic, with strong emphasis on improving therapeutic outcomes and enhancing patients\' quality of life. This ongoing innovation cycle is expected to sustain competitive intensity and foster further market expansion.
Recent Developments:
On January 31, 2025, AB Science announced the launch of a new Phase 3 clinical trial to assess its investigational oral drug, masitinib, in ALS patients showing typical disease progression who have not yet lost full physical function.
On February 7, 2025, Eledon Pharmaceuticals revealed the inclusion of Tegoprubart in the immunosuppression protocol during its second successful transplant of a genetically modified pig kidney into a human recipient.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
AB Science
Biogen Inc.
Biohaven Pharmaceutical (Pfizer, Inc.)
BrainStorm Therapeutics, Inc.
Corestemchemon Inc.
Eledon Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd
Ionis Pharmaceuticals, Inc.
ITF Pharma GmbH
Mitsubishi Tanabe Pharma Corporation
Otsuka America Pharmaceutical, Inc.
Sun Pharmaceutical Industries Ltd.
Others
GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032
Sporadic ALS
Familial ALS
GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032
Medication
o Riluzole
o Edaravone
o Nuedexta
o Other medication types
Stem cell therapy
Other treatment types
GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies
GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
o U.S.
o Canada
Europe
o Germany
o UK
o France
o Italy
o Spain
o The Netherlands
o Sweden
o Russia
o Poland
o Rest of Europe
Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Thailand
o Philippines
o Rest of APAC
Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
The Middle East and Africa
o Saudi Arabia
o UAE
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Amyotrophic Lateral Sclerosis Treatment Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Type
2.1.2. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Treatment Type
2.1.3. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Distribution Channel
2.1.4. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Country
2.1.5. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Region
2.2. Competitive Insights
3. Amyotrophic Lateral Sclerosis Treatment Key Market Trends
3.1. Amyotrophic Lateral Sclerosis Treatment Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Amyotrophic Lateral Sclerosis Treatment Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Amyotrophic Lateral Sclerosis Treatment Market Opportunities
3.4. Amyotrophic Lateral Sclerosis Treatment Market Future Trends
4. Amyotrophic Lateral Sclerosis Treatment Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Amyotrophic Lateral Sclerosis Treatment Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Amyotrophic Lateral Sclerosis Treatment Market Landscape
6.1. Amyotrophic Lateral Sclerosis Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Amyotrophic Lateral Sclerosis Treatment Market – By Type
7.1. Overview
7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
7.1.2. Sporadic ALS
7.1.3. Familial ALS
8. Amyotrophic Lateral Sclerosis Treatment Market – By Treatment Type
8.1. Overview
8.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
8.1.2. Medication
8.1.2.1. Riluzole
8.1.2.2. Edaravone
8.1.2.3. Nuedexta
8.1.2.4. Other medication types
8.1.3. Stem cell therapy
8.1.4. Other treatment types
9. Amyotrophic Lateral Sclerosis Treatment Market – By Distribution Channel
9.1. Overview
9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
9.1.2. Hospital Pharmacies
9.1.3. Online Providers
9.1.4. Drug Stores and Retail Pharmacies
10. Amyotrophic Lateral Sclerosis Treatment Market– By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
10.2.1. Overview
10.2.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3.16. Rest of Europe
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4.15. Rest of APAC
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6.13. Rest of MEA
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11. Key Vendor Analysis- Amyotrophic Lateral Sclerosis Treatment Industry
11.1. Competitive Dashboard
11.1.1. Competitive Benchmarking
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. AB Science
11.2.2. Biogen Inc.
11.2.3. Biohaven Pharmaceutical (Pfizer, Inc.)
11.2.4. BrainStorm Therapeutics, Inc.
11.2.5. Corestemchemon Inc.
11.2.6. Eledon Pharmaceuticals, Inc.
11.2.7. F. Hoffmann-La Roche Ltd
11.2.8. Ionis Pharmaceuticals, Inc.
11.2.9. ITF Pharma GmbH
11.2.10. Mitsubishi Tanabe Pharma Corporation
11.2.11. Otsuka America Pharmaceutical, Inc.
11.2.12. Sun Pharmaceutical Industries Ltd.
11.2.13. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
